Evidence map›Paper›PMID 18248689›Full record

Trial reportThe international journal of neuropsychopharmacology2008

Evaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine in methamphetamine-dependent human volunteers.

Richard De La Garza, Steve Shoptaw, Thomas F Newton

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The international journal of neuropsychopharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Rivastigmine reduces "Likely to use methamphetamine" in methamphetamine-dependent volunteers.Progress in neuro-psychopharmacology & biological psychiatry · 2012
    Trial
  5. Trial
  6. Trial
  7. Galantamine improves sustained attention in chronic cocaine users.Experimental and clinical psychopharmacology · 2011
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Pharmacotherapy for stimulant-related disorders.Current psychiatry reports · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Richard De La GarzaDavid Geffen School of Medicine, University of California, Los Angeles, CA, USA. rdlgarza@mednet.ucla.edu
Steve Shoptaw
Thomas F Newton
University of California, Los Angeles · US

Funding

ZDV &3TC NEVIRAPINE COMBINATION THERAPY IN HIV 1 INFECTED INFANTS &M01RR000865 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WASHINGTON, ARNOLD E. · 1985 to 2011
$43.4M
UCLA Medication Development Unit for Stimulant AbuseP50DA018185 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHOPTAW, STEVEN J · 2004 to 2009
$5.8M
Clinical Research Education for Drug Abuse ProfessionalsR25DA014593 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEWTON, THOMAS FREDERICK · 2002 to 2006
$1.3M
Assess of Stress Effects in Methamphetamine DependenceK24DA017754 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEWTON, THOMAS FREDERICK · 2005 to 2010
$727k
NCRR NIH HHS M01 RR000865NCRR NIH HHS RR 00865NIDA NIH HHS DA 14593NIDA NIH HHS DA 17754NIDA NIH HHS DA 18185NIDA NIH HHS K24 DA017754NIDA NIH HHS P50 DA018185NIDA NIH HHS R25 DA014593
6 · The paper itself

Abstract

Acetylcholine (ACh) has been implicated in the reinforcing and locomotor-activating effects produced by methamphetamine (Meth). Of interest, recent data suggest that acetylcholinesterase (AChE) inhibitors attenuate Meth-seeking behaviour in rats. We conducted this study in order to determine the safety (adverse events, mood changes, cardiovascular effects) and preliminary efficacy (subjective effects) of the AChE inhibitor rivastigmine (Riv) when tested in combination with Meth. Twenty-three non-treatment-seeking Meth-dependent participants resided in an in-patient unit at UCLA for 2mg i.v.) and Meth (day 5, 30mg, n=7) or Riv (1.5mg, n=9). On day 11, the subjects received saline and Meth infusions again (randomized to either 11:30 or 14:30 hours), under double-blind conditions. The data analyses compared across-study measures of adverse events and mood, and a post-randomization analysis of cardiovascular and subjective effects (on day 11). The data reveal that rivastigmine was not associated with increased adverse events or alterations in mood. As expected, acute Meth exposure (30mg, significantly attenuated Meth-induced increases in diastolic blood pressure, and self-reports of and (p<0.05). Taken together, the findings in the current report suggest that pharmacological manipulations that enhance brain ACh warrant continued investigation as potential treatments for Meth addiction.

Indexed as

MethamphetamineSubstance-Related DisordersAdolescentAdultAffectAnalysis of VarianceBlood PressureCardiovascular SystemDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationEvaluation Studies as TopicHeart RateHuman ExperimentationHumansMaleMethamphetamineNeuroprotective AgentsPhenylcarbamatesRivastigmine

Identifiers

PMID18248689
PMCPMC2581751
OpenAlexW2165479128

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.